Recent Study: Belgium Pharmaceuticals & Healthcare Report Q4 2013
Belgium's pharmaceutical and healthcare markets are struggling in the face of costcontainment measures. However, the government has little choice but to cut back on spending if it is to meet its European fiscal deficit target. Per capita spending on pharmaceuticals is high, and Belgium is an important location for research, clinical trials and new drug development, but drugmakers will increasingly find the government is less willing to reimburse expensive, innovative medicines. Given the ongoing economic troubles in the eurozone, we...
View full press release